Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPRAIS: Rabeximod add-on therapy in rheumatoid arthritis
2021-006665-38Phase 2Terminated
- Sponsor
- Cyxone
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rabeximod + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Change from baseline in DAS28-CRP at Week 16. Started Jun 2022; status: terminated.
02
Drugs
rabeximod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-006665-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006665-38.